Business Wire

TOKYO-NIGHT-&-LIGHT-PR

Share
J-Pop Stars Pump up the World’s Largest Projection Mapping Show at the Tokyo Metropolitan Government Building

A meteoric J-pop duo with a huge global following has pitched in to boost the world’s largest projection mapping show and help illuminate midsummer nights in Tokyo.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808176674/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

YOASOBI / Butai ni Tatte (Standing on the Stage) (Photo: Business Wire)

An artwork, combining YOASOBI’s up-tempo vocal and instrumental music with a riot of images and colors, made its debut on the TOKYO Night & Light program on July 26. The nightly show uses the exterior of the 243-meter-tall Tokyo Metropolitan Government (TMG) No. 1 Building as its screen. Three other projections created by internationally acclaimed artists also joined the menu over the same weekend.

YOASOBI – female vocalist Ikura, 23, and male singer-songwriter Ayase, 30 - has contributed the newly composed “Butai ni Tatte (Standing on the Stage),” which echoes the emotions of athletes ready for competition. The song has been adopted by Japan’s public broadcasting corporation NHK as a theme song for its sports programs, and its first Night & Light presentation was timed to coincide with the Paris Olympics opening ceremony.

For the first screening, a horde of people gathered at the Citizens’ Plaza at the foot of the 48-story building, a landmark in the business and entertainment hub of Shinjuku. They watched animated silhouette images of runners and other athletes romp around on the wall.

The Night & Light project has lived up to the TMG’s goal of creating a “new tourism resource to color Tokyo’s nightlife,” attracting 280,000 visitors in five months since its launch on February 25. Projected onto an area, 127 meters by 110 meters, the show has been certified by Guinness World Records™ as the “largest architectural projection-mapped display (permanent).”

Screened every half an hour between 7:30 p.m. and 9:30 p.m. at present, the program strings together a few projections for 15 minutes. On weekends and holidays, the series feature crowd pullers such as the world-famous Japanese movie monster Godzilla and a work inspired by traditional Japanese Ukiyo-e paintings. “Standing on the Stage,” 3.5 minutes long, is to be screened every night for the time being.

Meaning a “night out,” YOASOBI is a global household name five years after its debut. Its hit “Idol,” the theme tune for the TV animation “Oshi no Ko,” became the first Japanese song to top Billboard’s Global (excluding U.S.) chart in June last year. It was also acknowledged as Japan’s best popular song in terms of royalties in the year to March 2024.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240808176674/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone16.9.2024 08:00:00 CEST | Press release

On the International Identity Day ‘ID Day’, Thales reaffirms its dedication to supporting global identity initiatives and driving technological advancements that foster inclusion, security, and trust. Around the world, more than 850 million individuals do not have a legal identity, preventing them from claiming their rights and accessing fundamental citizen services e.g. health, education, employment. Thales has been working for more than thirty years to make trustworthy identities a reality for everyone, employing cutting-edge and responsible technology for biometrics and digital ID solutions. On September 16th, Thales celebrates the International Identity Day (ID Day), a symbolic day to highlight the United Nations' Sustainable Development Goal16.9 to provide a legal identity for all. ID Day is dedicated to raising awareness about the importance of legal identity as a fundamental human right and a key enabler of inclusive social and economic development. Thales supports global effort

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer14.9.2024 18:45:00 CEST | Press release

New antitumor response data from a range of doses and regimens unveiled today at Incyte investor eventThese results build upon safety and tolerability data presented earlier today during a mini-oral presentation at the European Society of Medical Oncology (ESMO) Congress 2024Findings support the initiation of a pivotal trial in ovarian cancer, expected to begin in 2025; additional plans to evaluate INCB123667 in combination with other treatments are underway Incyte (Nasdaq:INCY) today announced new early clinical data for INCB123667, a highly selective, potential first-in-class CDK2 inhibitor, in patients with advanced solid tumors. The trial results, presented during a mini-oral presentation at the European Society of Medical Oncology (ESMO) with new, updated data shared during the Company’s investor event, highlight the potential of INCB123667 as a differentiated treatment option for cancers with increased Cyclin E1 activity, amplification and/or overexpression in cells predictive of

Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium14.9.2024 16:30:00 CEST | Press release

- Phase 3 POD1UM-303/InterAACT2 trial met primary endpoint of progression-free survival and demonstrated improvement across secondary endpoints in patients with squamous cell anal carcinoma (SCAC) taking retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) - Late-breaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024 support the planned U.S. filing of a supplemental Biologics License Application (sBLA) for retifanlimab in SCAC by year-end 2024 - Incyte to host an in-person analyst and investor event to review key data at ESMO on Saturday, September 14, 2024 from 1:00-2:30 p.m. ET (7:00-8:30 p.m. CEST) Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-303/InterAACT2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy (carboplatin–paclitaxel) for the treatment of adults with inoperable locally recu

Irdeto Partners with Bitmovin to Deliver Industry-Leading Secure Low-Latency Streaming with Unmatched User Experience14.9.2024 10:00:00 CEST | Press release

This joint offering allows operators to benefit from seamless, high-quality streaming, extended device reach, and advanced advertising and security features Irdeto, the global leader in digital video platform experiences and security, and Bitmovin, the industry leader in video software solutions, today announced a strategic partnership to deliver enhanced secure video streaming experiences. This collaboration integrates Bitmovin’s renowned Player and Analytics suite into Irdeto Experience, the award-winning streaming platform trusted by top-tier operators worldwide. Together, they will provide streaming service providers, content owners, and pay-TV operators with cutting-edge solutions that address the critical need for low-latency streaming. The combination of Irdeto’s expertise in security and Bitmovin’s preeminent player offers a powerful and comprehensive solution. This joint offering allows operators to benefit from smooth, high-resolution streaming and advanced advertising and se

SCF Acquires Newpark Fluids Systems14.9.2024 02:40:00 CEST | Press release

SCF Partners, Inc. (“SCF”) is pleased to announce its acquisition of the Newpark Fluids Systems business (“NFS”), a leading global pure-play oil & gas and geothermal fluids solution provider, from Newpark Resources Inc. (NYSE: NR). Newpark Fluids Systems provides a full range of drilling & completion products and related technical services supported by an innovative digital modeling software suite, global supply chain and infrastructure to enhance the efficiency and productivity of our customers’ performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240913427560/en/ Newpark Fluid Systems’ CEO, David Paterson, commented, “We are thrilled to partner with SCF. This new partnership will be a source of enormous value creation for both our customers and the entire Newpark Fluids Systems team. Our global strategic growth plan will now accelerate under a new and focused board with significant energy experience and commitment.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye